In the present study, we reported SYNE1 mutations associated with worse prognosis in patients with ESCC, which is consistent with a previous report of patients with clear cell renal cell carcinoma showing that SYNE1 mutations correlate with a higher tumor mutation burden and poorer outcomes (25). The gene discussed is SYNE1; the disease is neoplasm.